Herantis Pharma Plc Announces Appointment of Investor Relations Team

Herantis Pharma Plc
Company release 04 Sep 2020 at 9:00 am

Herantis Pharma Plc
Company release September 4, 2020 at 9:00 AM Eastern European Summer Time

Herantis Pharma Plc (“Herantis” or “Company”) announced today that the company has appointed Julie Silber and Gabriela Urquilla of JG Investor Relations AB (“JG-IR”) as the new Investor Relations team, as of 1 September 2020.  

JG-IR is a Swedish based financial and healthcare communications firm with a strong track record supporting successful Nordic listed companies to help establish best-in-class investor relations and expand their exposure with key audiences in Nordic and global capital markets. Julie brings over 20 years of financial communications, equity analyst, public company CFO and IRO experience with notable private and publicly held companies in both EU and US.  Gabriela brings equity analyst and public company investor relations experience from Wall Street, and now Stockholm, in life sciences, medtech, and pharmaceuticals.

“We are very pleased to be working with JG-IR to ensure Herantis develops a best practice healthcare communications and investor relations program to support our continued development,” commented Craig Cook, CEO of Herantis.

For more information, please contact:
Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.